Trials / Terminated
TerminatedNCT02570789
Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy
A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess whether certain metabonomics and/or lipidomics features in correlation with pharmacokinetics before, during and after treatment with sunitinib or pazopanib in first line can predict toxicity and efficacy of sunitinib or pazopanib in metastatic clear cell renal cell carcinoma patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | patients with sunitinib or pazopanib | The treatment with sunitinib or pazopanib should comply with the recommendations written in the Belgian product information and the reimbursement criteria |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2018-12-01
- Completion
- 2021-03-01
- First posted
- 2015-10-07
- Last updated
- 2021-03-23
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02570789. Inclusion in this directory is not an endorsement.